Solstice Oncology Launches with $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology TherapyPorustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer
